

Angelo Sangiovanni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7179728/publications.pdf>

Version: 2024-02-01

76
papers

6,620
citations

94269

37
h-index

95083

68
g-index

78
all docs

78
docs citations

78
times ranked

7439
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	6.1	62
2	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. <i>Journal of Hepatology</i> , 2022, 76, 302-310.	1.8	48
3	Prothrombin induced by vitamin K absence or antagonist and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 350-359.	1.9	11
4	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.4	3
5	An Unprecedented Challenge: The North Italian Gastroenterologist Response to COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 109.	1.0	0
6	Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 64.	0.5	2
7	Reshape and secure HCC managing during COVID-19 pandemic: A single centre analysis of four periods in 2020 versus 2019. <i>Liver International</i> , 2021, 41, 3028-3032.	1.9	5
8	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. <i>Cancers</i> , 2021, 13, 5797.	1.7	13
9	Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 568-574.	0.5	40
10	Transjugular liver biopsy: The Tru-cut needle might be better for stiffer livers. <i>Digestive and Liver Disease</i> , 2020, 52, 1381-1382.	0.4	0
11	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3583.	1.7	16
12	Hepatic Fat Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. <i>Hepatology</i> , 2020, 72, 1912-1923.	3.6	48
13	Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e128-e129.	0.9	1
14	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	1.8	38
15	The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. <i>Liver International</i> , 2020, 40, 1987-1996.	1.9	44
16	Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. <i>Liver International</i> , 2019, 39, 1964-1974.	1.9	11
17	Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. <i>Annals of Hepatology</i> , 2019, 18, 318-324.	0.6	4
18	Deficient Natural Killer Cell NKG2D-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1165-1179.	3.6	48

#	ARTICLE	IF	CITATIONS
19	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1183-1191.e7.	2.4	79
20	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to <scp>IFN</scp> and cirrhosis regression. <i>Liver International</i> , 2018, 38, 1459-1467.	1.9	22
21	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules. <i>Journal of Hepatology</i> , 2018, 68, 485-492.	1.8	195
22	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Annals of Hepatology</i> , 2018, 17, 110-118.	0.6	20
23	Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it?. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 202-205.	0.7	0
24	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 15350-15364.	0.8	79
25	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>United European Gastroenterology Journal</i> , 2018, 6, 1039-1048.	1.6	54
26	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Liver International</i> , 2018, 38, 1624-1634.	1.9	25
27	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.4	41
28	Premalignant and Early Malignant Hepatocellular Lesions in Chronic Hepatitis/Cirrhosis. , 2018, , 487-505.		1
29	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	7.7	172
30	Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. <i>Liver International</i> , 2016, 36, 166-176.	1.9	19
31	Treatment of hepatocellular carcinoma: beyond international guidelines. <i>Liver International</i> , 2016, 36, 124-129.	1.9	67
32	A therapeutic conundrum: Delaying ablation of small nonresectable early hepatocellular carcinoma to facilitate liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 161-162.	1.3	2
33	Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>United European Gastroenterology Journal</i> , 2016, 4, 363-370.	1.6	16
34	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016, 65, 1754-1764.	6.1	108
35	Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan status in patients with a small hepatocellular carcinoma. <i>Liver Transplantation</i> , 2015, 21, 1259-1269.	1.3	35
36	Treatment of hepatocellular carcinoma: beyond international guidelines. <i>Liver International</i> , 2015, 35, 129-138.	1.9	93

#	ARTICLE	IF	CITATIONS
37	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. <i>Digestive Diseases</i> , 2015, 33, 735-744.	0.8	19
38	Hepatitis B virus (<scp>HBV</scp>) <scp>DNA</scp> integration in patients with occult <scp>HBV</scp> infection and hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2311-2317.	1.9	92
39	A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. <i>Journal of Hepatology</i> , 2015, 63, 1323-1333.	1.8	22
40	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015, 64, 1296-1302.	6.1	70
41	Vitamin D deficiency and liver cancer: More than just an epidemiological association?. <i>Hepatology</i> , 2014, 60, 1130-1132.	3.6	14
42	Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 60, 995-1001.	1.8	61
43	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1024-1030.	0.6	195
44	Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 1188-1193.	1.8	110
45	Advanced precancerous lesions in the liver. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 269-284.	1.0	46
46	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. <i>Digestive and Liver Disease</i> , 2013, 45, 43-49.	0.4	23
47	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. <i>Liver International</i> , 2013, 33, 771-779.	1.9	91
48	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e75982.	1.1	42
49	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	1.8	736
50	Re: Indeterminate 1-2 cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none?. <i>Hepatology</i> , 2012, 55, 651-651.	3.6	0
51	Guidelines for the management of hepatocellular carcinoma: still in need of standardization. <i>Chinese Clinical Oncology</i> , 2012, 1, 15.	0.4	0
52	How I manage my patients with hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 145-150.	1.9	2
53	Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. <i>Hepatology</i> , 2011, 53, 1549-1557.	3.6	77
54	Surveillance for hepatocellular carcinoma: A standard of care, not a clinical option. <i>Hepatology</i> , 2011, 54, 1898-1900.	3.6	12

#	ARTICLE	IF	CITATIONS
55	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. <i>Hepatology</i> , 2010, 52, 1723-1730.	3.6	67
56	The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. <i>Gut</i> , 2010, 59, 638-644.	6.1	358
57	Transarterial Chemoembolization with Epirubicin-eluting Beads versus Transarterial Embolization before Liver Transplantation for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 327-332.	0.2	132
58	The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 50, 746-754.	1.8	280
59	A 28-Year Study of the Course of Hepatitis B Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 136, 1629-1638.	0.6	285
60	Epidemiology of the Hepatocellular Carcinoma. , 2009, , 1-8.		1
61	Hepatitis C virus genotype 1b, cirrhosis, and risk of hepatocellular carcinoma. <i>Hepatology</i> , 2007, 47, 357-357.	3.6	2
62	The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. <i>Hepatology</i> , 2006, 43, 1303-1310.	3.6	527
63	Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. <i>Blood Cells, Molecules, and Diseases</i> , 2005, 35, 27-32.	0.6	24
64	The strategic role of staging in the treatment of HCC. <i>Hepatology</i> , 2004, 39, 552-553.	3.6	10
65	Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. <i>Gastroenterology</i> , 2004, 126, 1005-1014.	0.6	556
66	Etiology, natural history and treatment of hepatocellular carcinoma. <i>Antiviral Research</i> , 2003, 60, 145-150.	1.9	64
67	Segmental Transcatheter Arterial Chemoembolization Treatment in Patients with Cirrhosis and Inoperable Hepatocellular Carcinomas. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, 995-999.	0.2	31
68	Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 501-506.	0.8	30
69	Hepatocyte Proliferation and Risk of Hepatocellular Carcinoma in Cirrhotic Patients. <i>American Journal of Gastroenterology</i> , 2001, 96, 1575-1580.	0.2	38
70	High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. <i>Hepatology</i> , 1999, 29, 1704-1707.	3.6	87
71	Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study. <i>Hepatology</i> , 1998, 27, 853-856.	3.6	89
72	HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. <i>Journal of Hepatology</i> , 1998, 29, 701-706.	1.8	74

#	ARTICLE	IF	CITATIONS
73	Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. <i>Journal of Hepatology</i> , 1996, 25, 474-480.	1.8	49
74	Hepatocellular Carcinoma in Italian Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 1991, 325, 675-680.	13.9	773
75	Specificity of the Hepatitis C Virus Antibody ELISA in Patients With Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 1990, 82, 1784-1785.	3.0	3
76	Î²-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial. <i>Hepatology</i> , 1989, 9, 433-438.	3.6	106